

Published on *UCSF Department of Radiation Oncology* (<http://radonc.ucsf.edu>)

[Home](#) > [Our Team](#) > [Medical Faculty](#) > [Mary Feng](#)

Mary Feng

Mary Feng, M.D.

Vice Chair for Clinical Research



Professor, Department of Radiation Oncology

University of California, San Francisco
Gateway Medical Building
Box 4001, 1825 Fourth Street, Suite M2267
San Francisco, CA 94158
Phone: 415 502-7222
Fax: 415 476-7370
TTY: 415 885-3889

Make A Gift
Support Our Research

[1]

Professional Focus

Dr. Mary Feng specialized in treatment of gastrointestinal and hepatobiliary cancers. Her research focuses on technical and biological methods to individualize and adapt radiotherapy for each patient with pancreas and liver cancer to maximize the effectiveness of treatment. Her primary goals are 1) Improving outcomes for patients with pancreas and liver cancer

through novel combination treatments; 2) Adapting radiotherapy based on early blood and imaging biomarkers of tumor response and treatment effects on nearby organs; and 3) Evaluating the use of advanced technologies in radiotherapy.

Dr. Feng is Vice-Chair for Clinical Research, Clinical site director for the Mission Bay Clinic, and Director of Quality Assurance and Safety for the Department of Radiation Oncology at UCSF. She also serves on numerous national and international cancer organization panels and groups, including the National Comprehensive Cancer Network Pancreatic Adenocarcinoma Panel, the American Society of Clinical Oncology Gastrointestinal Cancer Guideline Advisory Group, and the American Society for Radiation Oncology IHE-RO Clinical Advisory Subcommittee as co-chair.

Education

1993-1997	Stanford University	BS	Honors in Biological Sciences
1998-2002	Washington University School of Medicine	MD	
2002-2003	University of Michigan Medical Center, Ann Arbor	Preliminary Medical Intern	
2003-2006	University of Michigan Medical Center, Ann Arbor	Resident	Radiation Oncology
2006-2007	University of Michigan Medical Center, Ann Arbor	Chief Resident	Radiation Oncology

Professional Experience

PRINCIPAL POSITIONS HELD			
2007-2009	University of Michigan, Ann Arbor	Clinical Instructor	Radiation Oncology
2009-2013	University of Michigan, Ann Arbor	Clinical Assistant Professor	Radiation Oncology
2011-2016	University of Michigan, Ann Arbor	Medical Director, MRI Program	Radiation Oncology
2012-2016	University of Michigan, Ann Arbor	Associate Director of Clinical Research	Radiation Oncology
2013-2016	University of Michigan, Ann Arbor	Clinical Associate Professor	Radiation Oncology
2016-present	University of California, San Francisco	Vice Chair for Clinical Research	Radiation Oncology

2016-2018	University of California, San Francisco	Associate Professor	Radiation Oncology
2018-present	University of California, San Francisco	Professor	Radiation Oncology

Awards & Honors

1996	Howard Hughes Medical Institute Summer Research Fellowship, Stanford University
1998	American Red Cross Volunteer of the Year, Palo Alto, California chapter
1998	Philpott Scholarship, Washington University School of Medicine
1999	Mallinckrodt Institute/Howard Hughes Medical Institute Summer Radiation Oncology Fellowship
2004	Third place presentation, Michigan Society of Therapeutic Radiation Oncology Resident Research Competition
2005	American Association for Women Radiologists Member-in-Training Award for Outstanding RSNA Presentation in Radiation Oncology
2006	American Association for Women Radiologists Member-in-Training Award for Outstanding ASTRO Presentation in Radiation Oncology
2007	Radiological Society of North America, Resident Research and Education Foundation Award
2007	American Society for Radiation Oncology plenary session presentation; abstract selected from 2036 total submissions from around the world.
2013	Two abstracts selected for presentation at the 2013 Best of ASTRO conference

Recent Significant Publications :

Cuneo KC, Chenevert TL, Ben-Josef E, Feng M, Greenson JK, Hussain HK, Simeone DM, Schipper JM, Anderson MA, Zalupski MM, Al-Hawary M, Galgan CJ, Rehemtulla A, Feng FY, Lawrence TS, Ross BD. **A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer.** Transl Oncol 2014;7(5):644-9. PMID: 25389460, PMCID: 4225651

Cuneo KC, Davis MA, Feng M, Novelli PM, Ensminger WD, Lawrence TS. **Low dose rate radiosensitization of hepatocellular carcinoma in vitro and in patients.** Transl Oncol 2014;7(4):472-8. PMID: 24956939, PMCID: 4202782

Jagsi R, Griffith, KA, Heimbürger D, Walker EM, Grills IS, Boike T, Feng M, Moran JM, Hayman J, Pierce LJ. **Choosing Wisely? Patterns and correlates of the use of hypofractionated whole-breast radiation therapy in the state of Michigan.** *Int. J. Rad. Onc. Biol. Phys* 2014;90(5):1010-1016. PMID: 25539366

Hsu SH, Cao Y, Lawrence TS, Tsien C, Feng M, Grodzki DM, Balter JM. **Quantitative characterizations of ultrashort echo (UTE) images for supporting air-bone separation in the head.** *Phys Med Biol* 2015;60(7):2869-2880. PMID: 25776205

Shumway D, Griffith KA, Pierce LJ, Feng M, Moran JM, Stenmark MH, Jagsi R, Hayman JA. **Wide variation in the diffusion of a new technology: Practice-based trends in intensity modulated radiation therapy (IMRT) utilization in the state of Michigan with implications for IMRT use nationally.** *J Oncol Pract* 2015;11(3):e373-379. PMID: 25736383

Davis EJ, Chugh R, Zhao L, Lucas DR, Biermann JS, Zalupski MM, Feng M, Wong SL, Jacobson J, Zyczynski L, Reinke D, Metko G, Baker LH, Schuetze SM. **A randomized, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localized, high-risk, soft tissue sarcoma.** *European J of Cancer* 2015;51(13):1794-1802. PMID: 26066736

Jagsi R, Griffith KA, Boike TP, Walker E, Nurushev T, Grills IS, Moran JM, Feng M, Hayman J, Pierce LJ. **Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: Comparative analysis of physician-assessed and patient-reported outcomes in a large multicenter cohort.** *JAMA Oncol.* 2015;1(7):918-30. doi: 10.1001/jamaoncol.2015.2590. PubMed PMID: 26247417

Zhou J, Fang CX, Shen J, Schipper JM, Zalupski MM, Minter RM, Simeone DM, Hart D, Eagle T, Kimmel GW, Vainshtein J, Lawrence TS, Feng M. **Definitive chemoradiation with full-dose gemcitabine for unresectable pancreatic cancer: Efficacy of involved field radiotherapy.** *Am J Clin Oncol.* 2015. doi: 10.1097/COC.0000000000000200. PubMed PMID: 26165418.

Wahl DR, Stenmark MH, Tao Y, Pollom E, Caoili EM, Lawrence TS, Schipper MJ, Feng M. **Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma.** *J Clin Oncol.* 2016;34(5):452-9. doi: 10.1200/JCO.2015.61.4925. PubMed PMID: 26628466; PMCID: PMC4872011

Paradis E, Cao Y, Lawrence TS, Tsien C, Feng M, Vineberg K, Balter JM. **Assessing the dosimetric accuracy of magnetic resonance-generated synthetic CT images for focal brain VMAT radiation therapy.** *Int J Radiat Oncol Biol Phys.* 2015;93(5):1154-61. doi: 10.1016/j.ijrobp.2015.08.049. PubMed PMID: 26581151; PMCID: PMC4654706

Matuszak MM, Hadley SW, Feng M, Hayman JA, Brock KK, Burger P, Owen D, Suresh K, Lawrence TS, Ten Haken RK. **Enhancing safety and quality through pre-planning peer review for patients undergoing stereotactic body radiation therapy.** *Pract Radiat Oncol.* 2016;6(2):e39-46. doi: 10.1016/j.prro.2015.09.009. PubMed PMID: 26746815

Source URL: <http://radonc.ucsf.edu/mary-feng>

Links

[1] <http://radonc.ucsf.edu/make-gift>